Wolverine Trading’s Protara Therapeutics TARA Stock Holding History

Wolverine Trading’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$51.3K	Sell	11,636 -1,007	-8%	-$3.26K	﹤0.01%	5407
2025 Q2	$36.4K	Buy	+12,643	New	+$43.6K	﹤0.01%	4412

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Wolverine Trading's TARA Position: Q3 2025 in Review

Wolverine Trading reduced its Protara Therapeutics (TARA) stake by 8% in Q3 2025, selling an estimated $3.26K and leaving 11,636 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5407.

Wolverine Trading first reported a position in TARA in Q2 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold TARA as of Q3 2025.

Wolverine Trading held 11,636 shares of Protara Therapeutics worth $51.3K as of Q3 2025.
Wolverine Trading sold 1,007 Protara Therapeutics shares in Q3 2025, an estimated $3.26K.
Protara Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5407 holding.
Wolverine Trading first reported a position in Protara Therapeutics in Q2 2025 and has held it in 2 quarters since.
81 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.